Leapfrog Merger

Leapfrog Bio is a clinical-stage precision oncology company focused on accelerating the development of cancer therapies by retargeting clinical-stage molecules for tumors with specific loss-of-function (LOF) mutations. The company utilizes its proprietary OncoSLX Platform (also known as the Precision PGx Platform) to identify existing small-molecule drugs that can be developed to treat cancers driven by tumor suppressor gene mutations, which are historically difficult to drug. Its lead program, LFB190, is a first-in-class, oral small molecule BET inhibitor currently being prepared for Phase 2 clinical trials in solid tumors characterized by EP300 loss-of-function mutations. By leveraging a repeatable and scalable in vitro system, Leapfrog Bio aims to address the unmet needs of millions of patients whose cancers are driven by genetic signals hidden within biological complexity.